Inhalation of divalent and trivalent manganese mixture induces a Parkinson's disease model: Immunocytochemical and behavioral evidences

Neuroscience

Volumn 155, Issue 1, 2008, Pages 7-16

  Ordonez Librado J L ^a   Gutierrez Valdez, A L ^a   Colin Barenque L ^a   Anaya Martinez V ^a   Diaz Bech P ^b   Avila Costa, M R ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

manganese inhalation; motor behavior; Parkinson's disease experimental model; tyrosine hydroxylase

Indexed keywords

MANGANESE; MANGANESE CHLORIDE; TYROSINE 3 MONOOXYGENASE;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CONTROLLED STUDY; DEGENERATIVE DISEASE; IMMUNOCYTOCHEMISTRY; MALE; MESENCEPHALON; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA; TREMOR; VIDEOTAPE;

ACETATES; ANIMALS; BEHAVIOR, ANIMAL; CHLORIDES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEEDING BEHAVIOR; INHALATION EXPOSURE; MALE; MANGANESE COMPOUNDS; MICE; MOTOR ACTIVITY; ORGANOMETALLIC COMPOUNDS; PARKINSON DISEASE; PSYCHOMOTOR PERFORMANCE; SUBSTANTIA NIGRA; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 48949115357     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2008.05.012     Document Type: Article

References (84)

1. +3. Neurodegeneration 4 (1995) 329-334
2. Anderson J.G., Cooney P.T., and Erikson K.M. Inhibition of DAT function attenuates manganese accumulation in the globus pallidus. Environ Toxicol Pharmacol 23 (2007) 179-184
3. Archibald F.S., and Tyree C. Manganese poisoning and the attack of trivalent manganese upon catecholamines. Arch Biochem Biophy 256 (1987) 638-650
4. Aschner M., Erikson K.M., and Dorman D.C. Manganese dosimetry: species differences and implications for neurotoxicity. Crit Rev Toxicol 35 (2005) 1-32
5. Autissier N., Rochette L., Dumas P., Beley A., Loireau A., and Bralet J. Dopamine and norepinephrine turnover in various regions of the rat brain after chronic manganese chloride administration. Toxicology 24 (1982) 175-182
6. 5) inhalation. An immunocytochemical and cytological approach. Neurochem Res 7 (2004) 1357-1362
7. Betarbet R., Sherer T.B., and Greenamyre J.T. Animal models of Parkinson's disease. Bioessays 24 (2002) 308-318
8. Biernaskie J., Chernenko G., and Corbett D. Efficacy of rehabilitative experience declines with time after focal ischemic brain injury. J Neurosci 24 (2004) 1245-1254
9. Blanchard V., Raisman-Vozari R., Vyas S., Michel P.P., Javoy-Agid F., Uhl G., and Agid Y. Differential expression of tyrosine hydroxylase and membrane dopamine transporter genes in subpopulations of dopaminergic neurons of the rat mesencephalon. Brain Res Mol Brain Res 22 (1994) 29-38
10. Bonilla E. L-Tyrosine hydroxylase activity in the rat brain after chronic oral administration of manganese chloride. Neurobehav Toxicol 2 (1980) 37-41
11. Bowenkamp K.E., Lapchak P.A., Hoffer B.J., and Bickford P.C. Glial cell line-derived neurotrophic factor reverses motor impairment in 16-17 month old rats. Neurosci Lett 211 (1996) 81-84
12. Brouillet E.P., Shinobu L., McGarvey U., Hochberg F., and Beal M.F. Manganese injection into the rat striatum produces excitotoxic lesions by impairing energy metabolism. Exp Neurol 120 (1993) 89-94
13. Buonamici M., Maj R., Pagani F., Rossi A.C., and Khazan N. Tremor at rest episodes in unilaterally 6-OHDA induced substantia nigra lesioned rats: EEG-EMG and behavior. Neuropharmacology 25 (1986) 323-325
14. Calabresi P., Ammassari-Teule M., Gubellini P., Sancesario G., Morello M., Centonze D., Marfia G.A., Saulle E., Passino E., Picconi B., and Bernardi G. A synaptic mechanism underlying the behavioral abnormalities induced by manganese intoxication. Neurobiol Dis 8 (2001) 419-432
15. Calne D.B., Chu N.S., Huang C.C., Lu C.S., and Olanow W. Manganism and idiopathic parkinsonism: similarities and differences. Neurology 44 (1994) 1583-1586
16. Castiello U., Bennett K., Bonfiglioli C., Lim S., and Peppard R.F. The reach-to-grasp movement in Parkinson's disease: response to a simultaneous perturbation of object position and object size. Exp Brain Res 125 (1999) 453-462
17. Cenci M.A., Whishaw I.Q., and Schallert T. Animal models of neurological deficits: how relevant is the rat?. Nat Rev Neurosci 3 (2002) 574-579
18. Chandra S.V., and Shukla G.S. Concentrations of striatal catecholamines in rats given manganese chloride through drinking water. J Neurochem 36 (1981) 683-687
19. Chen J.Y., Tso G.C., Zhao Q., and Zheng W. Differential cytotoxicity of Mn(III): Special references to mitochondrial [Fe-S] containing enzymes. Toxicol Appl Pharmacol 175 (2001) 160-168
20. Chun H.S., Lee H., and Son J.H. Manganese induces endoplasmic reticulum (ER) stress and activates multiple caspases in nigral dopaminergic neuronal cells, SN4741. Neurosci Lett 316 (2001) 5-8
21. Ciliax B.J., Drash G.W., Staley J.K., Haber S., Mobley C.J., Miller G.W., Mufson E.J., Mash D.C., and Levey A. Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol 409 (1999) 38-56
22. Concise International Chemical Assessment (CICADs) (2001) Manganese and its compounds, document 12. World Health Organization (WHO), Geneva, Switzerland.
23. Cook D., Fahn S., and Brait K. Chronic manganese intoxication. Arch Neurol 30 (1974) 59-64
24. Damier P., Hirsch E.C., Agid Y., and Graybiel A.M. The substantia nigra of the human brain II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122 (1999) 1437-1448
25. 2 on striatal and nigral synthesis and levels of dopamine and cofactor. Neurotoxicol Teratol 13 (1991) 483-487
26. Decker D.E., Althaus J.S., Buxser S.E., VonVoigtlander P.F., and Ruppel P.L. Competitive irreversible inhibition of dopamine uptake by 6-hydroxydopamine. Res Commun Chem Pathol Pharmacol 79 (1993) 195-208
27. Díaz-Véliz G., Mora S., Gómez P., Dossi M.T., Montiel J., Arriagada C., Aboitiz F., and Segura-Aguilar J. Behavioral effects of manganese injected in the rat substantia nigra are potentiated by dicumarol, a DT-diaphorase inhibitor. Pharmacol Biochem Behav 77 (2004) 245-251
28. Donaldson J. The physiopathologic significance of manganese in brain: Its relation to schizophrenia and neurodegenerative disorders. Neurotoxicology 8 (1987) 451-462
29. Donaldson J., McGregor D., and LaBellaF. Manganese neurotoxicity: a model for free radical mediated neurodegeneration?. Can J Physiol Pharmacol 60 (1982) 1398-1405
30. Dunnett S.B., and Björklund A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399 Suppl (1999) A32-A39
31. Emborg M. Evaluation of animal models of Parkinson's disease for neuroprotective strategies. J Neurosci Methods 139 (2004) 121-143
32. Erikson H., Mägiste K., Plantin L.O., Fonnum F., Hedström K.G., Theodorsson-Norheim E., Kristensson K., Stålberg E., and Heilbronn E. Effects of manganese oxide on monkeys as revealed by a combined neurochemical, histological and neurophysiological evaluation. Arch Toxicol 61 (1987) 46-52
33. Erikson K., John C., Jones S., and Aschner M. Manganese accumulation in striatum of mice exposed to toxic doses is dependent upon a functional dopamine transporter. Environ Toxicol Pharmacol 20 (2005) 390-394
34. Farr T.D., and Whishaw I.Q. Quantitative and qualitative impairments in skilled reaching in the mouse (Mus musculus) after a focal motor cortex stroke. Stroke 33 (2002) 1869-1875
35. Fernagut P.O., Diguet E., Labattu B., and Tison F. A simple method to measure stride length as an index of nigro-striatal dysfunction in mice. J Neurosci Methods 113 (2002) 123-130
36. Fortoul T.I., Salgado R.C., Moncada S.G., Sánchez I.G., López I.E., Espejel G., Calderón N.L., and Saldivar L. Ultrastructural findings in the murine nonciliated bronchiolar cells (NCBC) alter subacute inhalation of lead acetate. Acta Vet Brno 68 (1999) 51-55
37. García-Hernández F., Pacheco-Cano M.T., and Drucker-Colín R. Reduction of motor impairment by adrenal medulla transplants in aged rats. Physiol Behav 54 (1993) 589-598
38. Giasson B.I., Duda J.E., Quinn S.M., Zhang B., Trojanowski J.Q., and Lee V.M. Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein. Neuron 34 (2002) 521-533
39. Goldberg M.S., Fleming S.M., Palacino J.J., Cepeda C., Lam H.A., Bhatnagar A., Meloni E.G., Wu N., Ackerson L.C., Klapstein G.J., Gajendiran M., Roth B.L., Chesselet M.F., Maidment N.T., Levine M.S., and Shen J. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 278 (2003) 43628-43635
40. Graham D.G. Catecholamine toxicity: a proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease. Neurotoxicology 5 (1984) 83-96
41. Guilarte T.R., Chen M.-K., McGlothan J.L., Verina T., Wong D.F., Zhou Y., Alexander M., Rohde C.A., Syversen T., Decamp E., et al. Nigrostriatal dopamine system dysfunction and subtle motor function deficits in manganese-exposed non-human primates. Exp. Neurol 202 (2006) 381-390
42. Gupta S.K., Murthy R.C., and Chandra S.V. Neuromelanin in manganese-exposed primates. Toxicol Lett 6 (1980) 17-20
43. Gwiazda R.H., Lee D., Sheridan J., and Smith D.R. Low cumulative manganese exposure affects striatal GABA but not dopamine. Neurotoxicology 95 (2002) 1-8
44. Gwiazda R.H., Lucchini R., and Smith D. Adequacy and consistency of animal studies to evaluate the neurotoxicity of chronic low-level manganese exposure in humans. J Toxicol Environ Health Part A 70 (2007) 594-605
45. Haber S.N., Ryoo H., Cox C., and Lu W. Subsets of midbrain dopaminergic neurons in monkeys are distinguished by different levels of mRNA for the dopamine transporter: comparison with the mRNA for the D2 receptor, tyrosine hydroxylase and calbindin immunoreactivity. J Comp Neurol 362 (1995) 400-410
46. HaMai D., and Bondy S.C. Oxidative basis of manganese neurotoxicity. Ann N Y Acad Sci 1012 (2004) 129-141
47. HaMai D., Campbell A., and Bondy S.C. Modulation of oxidative events by multivalent manganese complexes in brain tissue. Free Radic Biol Med 31 (2001) 763-768
48. Hastings T.G., Lewis D.A., and Zigmond M.J. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci U S A 93 (1996) 1956-1961
49. Hirata Y., Kiuchi K., and Nagatsu T. Manganese mimics the action of 1-methyl-4-phenylpyridinium ion, a dopaminergic neurotoxin, in rat striatal tissue slices. Neurosci Lett 311 (2001) 53-56
50. Ingersoll R., Montgomery Jr. E., and Aposhian H. Central nervous system toxicity of manganese. II: cocaine or reserpine inhibit manganese concentration in the rat brain. Neurotoxicology 20 (1999) 467-476
51. Jackson S.R., Jackson G.M., and Hindle J.V. The control of bimanual reach-to-grasp movements in hemiparkinsonian patients. Exp Brain Res 132 (2000) 390-398
52. Lang E., and Lozano A.M. Parkinson's disease. First of two parts. N Engl J Med 339 (1998) 1044-1053
53. Lindner M.D., Cain C.K., Plone M.A., Frydel B.R., Blaney T.J., Emerich D.F., and Hoane M.R. Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats. Behav Brain Res 102 (1999) 1-16
54. Liu X., Sullivan K.A., Madl J.E., Legare M., and Tjalkens R.B. Manganese-induced neurotoxicity: The role of astroglial-derived nitric oxide in striatal interneuron degeneration. Toxicol Sci 91 (2006) 521-531
55. MacLellan C.L., Gyawali S., and Colbourne F. Skilled reaching impairments follow intrastriatal hemorrhagic stroke in rats. Behav Brain Res 175 (2006) 82-89
56. Metz G.A., Farr T., Ballermann M., and Whishaw I.Q. Chronic levodopa therapy does not improve skilled reach accuracy or reach range on a pasta matrix reaching task in 6-OHDA dopamine-depleted (hemi-Parkinson analogue) rats. Eur J Neurosci 14 (2001) 27-37
57. Nachtman J.P., Tubben R.E., and Commissaris R.L. Behavioral effects of chronic manganese administration in rats: locomotor activity studies. Neurobehav Toxicol Teratol 8 (1986) 711-715
58. Normandin L., Panisset M., and Zayed J. Manganese neurotoxicity: behavioral, pathological, and biochemical effects following various routes of exposure. Rev Environ Health 17 (2002) 189-217
59. Ogawa N., Hirose Y., Ohara S., Ono T., and Watnabe Y. A simple quantitative bradykinesia test in MPTP-treated mice. Res Commun Chem Pathol Pharmacol 50 (1985) 435-441
60. Olanow C.W. Manganese-induced parkinsonism and Parkinson's disease. Ann N Y Acad Sci 1012 (2004) 209-223
61. Olanow C.W., and Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 22 (1999) 123-144
62. Pal P.K., Samii A., and Calne D.B. Manganese neurotoxicity: a review of clinical features, imaging and pathology. Neurotoxicology 20 (1999) 227-238
63. Perl D.P., and Olanow C.W. The neuropathology of manganese-induced parkinsonism. J Neuropathol Exp Neurol 66 (2007) 675-682
64. Permual A.S., Gopal V.B., Tordzro W.K., Cooper T.B., and Cadet J.L. Vitamin E attenuates the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain. Brain Res Bull 29 (1992) 699-701
65. Perry T.A., Torres E.M., Czech C., Beyreuther K., Richards S., and Dunnett S.B. Cognitive and motor function in transgenic mice carrying excess copies of the 695 and 751 amino acid isoforms of the amyloid precursor protein gene. Alzheimers Res 1 (1995) 5-14
66. 2) on the absorption and cerebral distribution of manganese in rats. Arch Toxicol 71 (1997) 223-230
67. Salehi F., Normandin L., Krewski D., Kennedy G., Philippe S., and Zayed J. Neuropathology, tremor and electromyogram in rats exposed to manganese phosphate/sulfate mixture. J Appl Toxicol 26 (2006) 419-426
68. Schallert T., Petrie B.F., and Whishaw I.Q. Neonatal dopamine depletion: spared and unspared sensorimotor and attentional disorders and effects of further depletion in adulthood. Psychobiology 17 (1989) 386-396
69. Schober A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 318 (2004) 215-224
70. Shukla G.S., and Singhal R.L. The present status of biological effects of toxic metals in the environment: lead, cadmium, and manganese. Can J Physiol Pharmacol 62 (1984) 1015-1031
71. Sistrunk S.C., Ross M.K., and Filipov N.M. Direct effects of manganese compounds on dopamine and its metabolite Dopac: An in vitro study. Environ Toxicol Pharmacol 23 (2007) 286-296
72. Sloot W.N., van der Sluijs-Gelling A.J., and Gramsbergen J.B.P. Selective lesions by manganese and extensive damage by iron after injection into rat striatum or hippocampus. J Neurochem 62 (1994) 205-216
73. Sloot W.N., Korf J., Koster J.F., DeWit L.E., and Gramsbergen J.B. Manganese-induced hydroxyl radical formation in rat striatum is not attenuated by dopamine depletion or iron chelation in vivo. Exp Neurol 138 (1996) 236-245
74. Struve M.F., McManus B.E., Wong B.A., and Dorman D.C. Basal ganglia neurotransmitter concentrations in rhesus monkeys following subchronic manganese sulfate inhalation. Am J Ind Med 50 (2007) 772-778
75. Thiruchelvam M., Brockel B.J., Richfield E.K., Baggs R.B., and Cory-Slechta D.A. Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease?. Brain Res 873 (2000) 225-234
76. Thiruchelvam M., Richfield E.K., Baggs R.B., Tank A.W., and Cory-Slechta D.A. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J Neurosci 20 (2000) 9207-9214
77. Tomas-Camardiel M., Herrera A.J., Venero J.L., Cruz-Sanchez-Hidalgo M., Cano J., and Machado A. Differential regulation of glutamic acid decarboxylase mRNA and tyrosine hydroxylase mRNA expression in the aged manganese-treated rats. Mol Brain Res 103 (2002) 116-129
78. Uhl G.R. Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Ann Neurol 43 (1998) 555-560
79. Ungerstedt U. Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 367 (1971) 95-122
80. Whishaw I.Q., Pellis S.M., Gorny B.P., and Pellis V.C. The impairments in reaching and the movements of compensation in rats with motor cortex lesions: an endpoint, videorecording, and movement notation analysis. Behav Brain Res 42 (1991) 77-91
81. Whishaw I.Q., Suchowersky O., Davis L., Sarna J., Metz G.A., and Pellis S.M. Impairment of pronation, supination, and body co-ordination in reach-to-grasp tasks in human Parkinson's disease (PD) reveals homology to deficits in animal models. Behav Brain Res 133 (2002) 165-176
82. Wright A.K., Atherton J.F., Norrie L., and Arbuthnott G.W. Death of dopaminergic neurones in the rat substantia nigra can be induced by damage to globus pallidus. Eur J Neurosci 20 (2004) 1737-1744
83. Yamada M., Ohno S., Okayasu I., Hatakeyama S., Watanabe H., Ushio K., and Tsukagoshi H. Chronic manganese poisoning: a neuropathological study with determination of manganese distribution in the brain. Acta Neuropathol 70 (1986) 273-278
84. Zhang S., Fitsanakis V.A., Gu G., Jing D., Ao M., Amarnath V., and Montine T.J. Manganese ethylene-bis-dithiocarbamate and selective dopaminergic neurodegeneration in rat: a link through mitochondrial dysfunction. J Neurochem 84 (2003) 336-346